Supply and clinical application of Actinium-225 and Bismuth-213
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
MORGENSTERN Alfred;
APOSTOLIDIS Christos;
BRUCHERTSEIFER Frank;
2020-03-12
W B SAUNDERS CO-ELSEVIER INC
JRC118726
0001-2998 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC118726,
10.1053/j.semnuclmed.2020.02.003 (online),
Additional supporting files
| File name | Description | File type | |
|---|
